.Attribute Medicine, Published online: 16 September 2024 doi:10.1038/ s41591-024-03244-8In the observational SCRUM-Japan GOZILA research, after a mean consequence of 11 months, patients with metastatic intestinal tumors that obtained biomarker-matched treatments based upon flowing growth DNA profiling presented a better clinical perk than those receiving unequaled treatment.